Loading...
XKRX
027360
Market cap318mUSD
Jul 10, Last price  
4,030.00KRW
1D
6.90%
1Q
-52.59%
IPO
234.44%
Name

AJU IB INVESTMENT CO LTD

Chart & Performance

D1W1MN
XKRX:027360 chart
P/E
57.32
P/S
15.04
EPS
70.31
Div Yield, %
1.24%
Shrs. gr., 5y
0.58%
Rev. gr., 5y
-17.60%
Revenues
31.70b
-29.58%
22,618,598,68050,586,619,38074,202,757,65060,233,546,51565,471,966,05631,462,440,88318,565,485,07935,224,299,00083,414,768,00059,382,101,00023,798,297,00053,740,828,00045,009,326,00031,696,034,000
Net income
8.32b
0.00%
-5,805,914,0706,524,479,5509,626,506,18011,680,024,09715,087,852,43116,113,088,79614,562,286,37316,288,676,00049,437,362,00039,333,565,0002,039,025,00016,601,631,0008,318,603,0008,318,265,000
CFO
26.37b
+9.55%
30,569,32025,496,704,73028,348,397,29065,178,233,85528,482,612,508-3,733,738,716-8,550,201,91125,933,977,00012,178,083,000117,372,036,0009,827,505,20043,038,944,00024,074,935,00026,374,119,000
Dividend
Dec 29, 202550 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aju IB Investment Co., Ltd., a venture capital and private equity subsidiary of AJU Corporation Co., Ltd., was established in 1974, initially operating as Kibo Technology Advancing Capital Co. Headquartered in Seoul, South Korea, with an additional office in Boston, Massachusetts, the firm is active in mezzanine financing, buyouts, corporate restructuring, and all stages of venture investments. Its primary focus is on small to medium-sized startup enterprises, predominantly in South Korea, though it also pursues international opportunities. For venture capital, it targets high-technology sectors, while private equity investments typically center on manufacturing. The firm's investment scope is broad, spanning information technology, including mobile service platforms, software, semiconductors, and digital content, as well as biotechnology, life sciences, and environmental solutions. It also delves into advanced information communication technologies such as the Internet of Things, artificial intelligence, smart car developments, and advanced materials. Specific medical areas of interest include companies developing immune system platform technology, oncology drugs, and ophthalmic pharmaceuticals. In South Korea, Aju IB Investment prioritizes companies that have achieved a rating of T5 or higher from technology credit bureaus. The Boston office maintains a specialized mandate, concentrating on therapeutics addressing significant unmet medical needs, enabling platform technologies with maturing lead candidates, potential partnerships with Korean pharmaceutical companies, and investments in medical devices and diagnostics. Financially, the firm generally invests between $0.87 million and $2.61 million for venture capital opportunities and between $4.36 million and $17.45 million for private equity transactions. Exit strategies commonly involve initial public offerings (IPOs) or mergers and acquisitions.
IPO date
Nov 21, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT